Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? (Q46102920)
Jump to navigation
Jump to search
scientific article published on 2 March 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? |
scientific article published on 2 March 2009 |
Statements
1 reference
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? (English)
1 reference
1 reference
Ian Tannock
1 reference
Bostjan Seruga
1 reference
Orit Freedman
1 reference
2 March 2009
1 reference
27
1 reference
11
1 reference
1919; author reply 1920-1
1 reference